FDA
-
-
-
-
-
-
-
BriaCell expands Phase 3 breast cancer study to 79 clinical sites
-
-
-
-
-
-
-
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
-
-
-
-
-
-
-
BriaCell Therapeutics (BCTX) Reports Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study
-
-
-
-
-
-
-
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer
-
-
-
-
-
-
-
BriaCell Therapeutics (BCTX) CEO Letter Issues to Shareholders
-
-
-
-
-
-
-
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting
-
-
-
-
-
-
-
BriaCell Therapeutics (BCTX) Reports Development Details of Bria-OTS Platform Technology
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

